Biomedical Systems teams up with Foundry Health for real-time trial data

Clinical study provider Biomedical Systems has formed a new collab with digital health company Foundry to be able to help pharma, biotech and CRO clients view trial data in real-time.

The two said in a joint statement that they will work on a cloud-based data management system that will allow sponsors “immediate access to clinical trial data” in real time.

“We’ve been a leader in the clinical trials industry for more than 40 years, and we continue to invest in technologies that improve data management capabilities for our clients,” said Tim Barrett, CEO, Biomedical Systems.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

“Our partnership with Foundry Health will result in a best-in-class data management solution, and we are dedicating significant resources to accelerate its availability.”

Brock Heinz, CEO, Foundry Health, added: “The partnership with Biomedical Systems will provide clients a continuum of data management for all phases of study.

“Biomedical Systems will focus on applications in phases two through four, while Foundry Health will continue to service clients, concentrating on phase one. We believe the product we are developing together will ultimately transform the way data is managed and accessed within clinical trials.”

Biomedical said the new system will be “phased in over time” but will eventually be made available to all of its clients. A timeline of this process, or financial details of the collab, were not given.

- check out the release

Related Articles:
Medtronic backs stealthy Foundry startup as it nabs $7.5M for novel remote patient monitoring
Stealth Foundry grad Twelve racks up $35M for percutaneous mitral valve replacement


Suggested Articles

Clinical trial firm Phesi’s new report is some grim reading for the life science industry: Studies for new drugs are still suffering.

Tempus fugit: And time especially flies when it comes clinical trials. Covance is teaming up with the suitably named Tempus to clip its wings.

PPD has raised its quarterly guidance after weathering the COVID-19 storm and is immediately making a secondary offering of 38 million shares.